
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Having trouble viewing?
Once you access the file, position your mouse over the top middle for a toolbar:



